We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Kidney Function Decline Linked with Inflammatory Marker Levels

By LabMedica International staff writers
Posted on 15 Oct 2018
Print article
Image: Higher levels of the inflammatory biomarker soluble tumor necrosis factor receptor-1 (sTNFR-1) are tied to kidney decline in healthy adults (Photo courtesy of Enbrel).
Image: Higher levels of the inflammatory biomarker soluble tumor necrosis factor receptor-1 (sTNFR-1) are tied to kidney decline in healthy adults (Photo courtesy of Enbrel).
Tumor necrosis factor receptor-1 (TNFR-1), which plays a causative role in endothelial cell dysfunction and inflammation, is expressed on the cell surface in glomerular and peritubular capillary endothelium of the kidneys.

Higher soluble TNF receptor-1 (sTNFR-1) concentrations are associated with kidney disease progression among persons with established diabetic kidney disease. Previous studies have demonstrated that blood levels of sTNFR-1 are linked with kidney disease progression in individuals with established kidney disease.

Scientists at the University of Washington School of Medicine (Seattle, WA, USA) and their colleagues conducted a multi-ethnic study of 2,548 adults with an average age of 61 years and 51% were women. Study participants were generally free of known kidney or heart disease at the start of the study, when sTNFR-1 levels were measured. The team tested associations between baseline sTNFR-1 concentrations and 10-year decline in estimated glomerular filtration rate (eGFR: incident ≥40% decline and annual proportional decline). Serum creatinine concentrations were determined at enrollment and study years 3, 5, and 10.

The scientists reported that the mean baseline eGFR was 79 mL/min per 1.73 m2. Serum sTNFR-1 was inversely associated with baseline eGFR. Over median follow-up of 9.3 years, 110 participants developed ≥40% decline in eGFR; each SD higher concentration of sTNFR1 was associated with higher risk of 40% eGFR decline (adjusted hazard ratio, 1.43; 95% confidence interval [95% CI], 1.16 to 1.77). The highest sTNFR-1 tertile was associated with adjusted annualized decline in eGFR of 1.94% (95% CI, 1.79 to 2.09). Associations persisted across subgroups defined by demographics, hypertension, diabetes, and baseline CKD status.

The authors concluded that elevated serum sTNFR-1 concentrations are associated with faster declines in eGFR over the course of a decade in a multiethnic population, independent of previously known risk factors for kidney disease progression. sTNFR-1 was associated with substantial differences in kidney function decline over time. Rates of decline over 10 years were nearly 4-times higher among people in the highest versus lowest sTNFR-1 categories. This association was independent of previously known risk factors for kidney disease progression and persisted across multiple sub-groups of participants.

Pavan K. Bhatraju, MD, MSc, the lead author of the study, said, “Many people continue to progressively lose kidney function despite treatment with current medications. New treatments are urgently needed to help prevent or slow the loss of kidney function. Our studies identify a novel marker that is strongly related to kidney function decline over time in a large multi-ethnic cohort and suggest follow up studies are warranted to investigate the potential role of sTNFR-1 in the development of kidney function decline.” The study was published on October 4, 2018, in the Journal of the American Society of Nephrology.

Related Links:
University of Washington School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.